318 related articles for article (PubMed ID: 38035566)
1. Anticoagulation in Patients with Chronic Kidney Disease.
Elenjickal EJ; Travlos CK; Marques P; Mavrakanas TA
Am J Nephrol; 2024; 55(2):146-164. PubMed ID: 38035566
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
[TBL] [Abstract][Full Text] [Related]
5. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
Shah S; Norby FL; Datta YH; Lutsey PL; MacLehose RF; Chen LY; Alonso A
Blood Adv; 2018 Feb; 2(3):200-209. PubMed ID: 29378726
[TBL] [Abstract][Full Text] [Related]
7. A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease.
Starr JA; Pinner NA; Mannis M; Stuart MK
Ann Pharmacother; 2022 Jun; 56(6):691-703. PubMed ID: 34459281
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban: A direct oral anticoagulant.
Poulakos M; Walker JN; Baig U; David T
Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease.
Parker K; Hartemink J; Saha A; Mitra R; Lewis P; Power A; Choudhuri S; Mitra S; Thachil J
J Nephrol; 2022 Nov; 35(8):2015-2033. PubMed ID: 36006608
[TBL] [Abstract][Full Text] [Related]
11. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
Harrington J; Carnicelli AP; Hua K; Wallentin L; Patel MR; Hohnloser SH; Giugliano RP; Fox KAA; Hijazi Z; Lopes RD; Pokorney SD; Hong H; Granger CB
Circulation; 2023 Jun; 147(23):1748-1757. PubMed ID: 37042255
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis.
Chen HY; Ou SH; Huang CW; Lee PT; Chou KJ; Lin PC; Su YC
Clin Drug Investig; 2021 Apr; 41(4):341-351. PubMed ID: 33709339
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
14. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
15. The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Oh HJ; Ryu KH; Park BJ; Yoon BH
Medicine (Baltimore); 2021 Mar; 100(11):e25216. PubMed ID: 33726018
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.
Bhatia HS; Bailey J; Unlu O; Hoffman K; Kim RJ
Pacing Clin Electrophysiol; 2019 Nov; 42(11):1463-1470. PubMed ID: 31599969
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
[TBL] [Abstract][Full Text] [Related]
18. Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
Jackevicius CA; Lu L; Ghaznavi Z; Warner AL
Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007230. PubMed ID: 33541109
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
20. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
